Barclays
BOLD

Barclays’s Boundless Bio BOLD Stock Holding History

Barclays’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2
Closed -$2 – 5527
2025
Q4 		$2 Hold
2
– – ﹤0.01% 5188
2025
Q3 		$2 Hold
2
– – ﹤0.01% 5446
2025
Q2 		$2 Sell
2
-17,853
-100% -$23.7K ﹤0.01% 5193
2025
Q1 		$27K Sell
17,855
-8,314
-32% -$17.2K ﹤0.01% 4744
2024
Q4 		$75.9K Buy
26,169
+17,536
+203% +$51.1K ﹤0.01% 4653
2024
Q3 		$30K Sell
8,633
-8,843
-51% -$32K ﹤0.01% 4840
2024
Q2 		$67.6K Buy
17,476
+2,476
+17% +$23.7K ﹤0.01% 4085
2024
Q1 		$214K Buy
+15,000
New +$214K ﹤0.01% 4083

Other funds holding BOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Barclays's BOLD Position: Q1 2026 in Review

Barclays sold out of Boundless Bio (BOLD) in Q1 2026, closing a stake of 2 shares — an estimated $2 sold.

Barclays first reported a position in BOLD in Q1 2024 and held it in 8 quarters. The position peaked at $214K in Q1 2024. 36 funds tracked by Wall St. Rank hold BOLD as of Q1 2026.

  • Barclays reported no remaining Boundless Bio position as of Q1 2026 after selling out during the quarter.
  • Barclays sold 2 Boundless Bio shares in Q1 2026, an estimated $2.
  • Barclays first reported a position in Boundless Bio in Q1 2024 and held it in 8 quarters.
  • Barclays's Boundless Bio position peaked at $214K in Q1 2024.
  • 36 funds tracked by Wall St. Rank held Boundless Bio as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.